Jimmy Nee
Physician Assistant · Brooklyn, NYNPI 1023040979
Payments from drug & device makers
Across 269 payments — averaging $24.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$3K
- Johnson & Johnson$1K
- Gilead$915
- Merck$629
- Janssen Products, LP$275
- EMD Serono, Inc.$133
- plus $136 from 2 others
What the payments were for
- Food & beverage$6,23996%
- Education$2754%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 123 | $2,943 |
| Johnson & Johnson | 67 | $1,484 |
| Gilead | 43 | $915 |
| Merck | 24 | $629 |
| Janssen Products, LP | 3 | $275 |
| EMD Serono, Inc. | 5 | $133 |
| Irhythm Technologies, Inc. | 3 | $115 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,514 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TriumeqAbacavir/Dolutegravir/Lamivudi | 155 | $593,078 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 125 | $577,976 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 125 | $499,690 |
| PrezcobixDarunavir/Cobicistat | 132 | $332,228 |
| DescovyEmtricitabine/Tenofov Alafenam | 63 | $134,168 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 28 | $95,978 |
| TivicayDolutegravir Sodium | 32 | $67,992 |
| TrulicityDulaglutide | 50 | $49,942 |
| IsentressRaltegravir Potassium | 25 | $48,991 |
| VascepaIcosapent Ethyl | 63 | $21,547 |
| Abacavir-LamivudineAbacavir Sulfate/Lamivudine | 47 | $18,345 |
| JanuviaSitagliptin Phosphate | 17 | $15,341 |
| EliquisApixaban | 19 | $10,781 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $7,007 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $6,773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTriumeq, Tivicay | $2,943 | $661,069187 claims |
| GileadBiktarvy, Descovy | $915 | $633,858188 claims |
| Janssen Products, LPSymtuza | $275 | $577,976125 claims |
| Johnson & JohnsonPrezcobix | $1,484 | $332,228132 claims |
| MerckIsentress, Januvia | $629 | $64,33242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Brooklyn
- Kaitlyn NelsonBrooklyn$289K
- Melissa VelezBrooklyn$68K
- Steven KongBrooklyn$66K
- Hong ChenBrooklyn$57K
- Lindsey AxtBrooklyn$52K
- Gregory CelestinBrooklyn$41K
- Henry YuBronx$1M
- Michael AsbachAmherst$962K
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.